P01-92 - Early changes are associated with late changes of BDNF serum levels in inpatients with major depression during short-term antidepressant treatment

AUTHORS:Kerstin Johansson, Karolina Thömkvist, Ingmar Skoog and Sacuiu SF* (*presenter)OBJECTIVE:To determine the effects of electroconvulsive therapy (ECT) in major depression in relation to the development of dementia during long-term follow-up.METHOD:In an observational clinical prospective study of consecutive patients 70 years and older diagnosed with major depression at baseline 2000-2004 (n=1090), who were free of dementia and received antidepressant treatment, with or without ECT, we sought to determine if cognitive decline (mild cognitive impairment and dementia) during 15 -year follow-up was associated with receiving ECT at baseline. The control group was selected among the participants in the Gothenburg H70 Birth Cohort Studies matched by age group and sex 1:1.RESULTS:Among patients with affective syndromes 7% received ECT. During follow-up, 157 patients were diagnosed with dementia, equal proportions among those who received ECT (14.5%) and those who did not receive ECT (14.5%). The relation between ECT and cognitive decline remained non-significant irrespective antidepressive medication or presence of mild cognitive impairment at baseline.CONCLUSION:Preliminary results indicate that ECT was not associated with the development of cognitive decline in the long-term in a hospital-based cohort of 70+ year-olds. The results remain to verify against controls from a representative community sample.

Download Full-text

Short-term prognosis in primary and secondary major depression

Journal of Affective Disorders ◽

10.1016/0165-0327(85)90057-6 ◽

1985 ◽

Vol 9 (3) ◽

pp. 265-270 ◽

Cited By ~ 13

Author(s):

William Coryell ◽

Mark Zimmerman ◽

Bruce Pfohl

Keyword(s):

Major Depression ◽

Short Term

Download Full-text

Cyclosporine increases ischemia-induced endothelial progenitor cell mobilization through manipulation of the CD26 system

AJP Regulatory Integrative and Comparative Physiology ◽

10.1152/ajpregu.00543.2007 ◽

2008 ◽

Vol 294 (3) ◽

pp. R811-R818 ◽

Cited By ~ 31

Author(s):

Chao-Hung Wang ◽

Wen-Jin Cherng ◽

Ning-I Yang ◽

Chia-Ming Hsu ◽

Chi-Hsiao Yeh ◽

...

Keyword(s):

Critical Role ◽

Serum Levels ◽

Blood Levels ◽

Short Term ◽

Endothelial Progenitor ◽

Beneficial Effects ◽

Dpp Iv ◽

Before And After ◽

Cell Mobilization

Cyclosporin A (CsA) improves the success rate of transplantation. The CD26/dipeptidylpeptidase IV (DPP IV) system plays a critical role in mobilizing endothelial progenitor cells (EPCs) from bone marrow. This study investigated whether CsA manipulates CD26/DPP IV activity and increases EPC mobilization. C57BL/6 mice were divided into control and CsA-treated groups. Before and after hindlimb ischemia was induced, circulating EPC number and serum levels of different cytokines were measured. Compared with the controls, CsA treatment significantly increased the blood levels of stroma-derived factor-1α and stem cell factor after ischemic stress ( P < 0.001). The CsA group displayed a significant increase in the number of circulating EPCs (sca-1+KDR+ and c-kit+CD31+ EPCs, both P < 0.05). In vivo, CsA caused a significant increase in the numbers of EPCs incorporated into the Matrigel and ischemic limbs ( P < 0.05). In the peripheral blood, CsA significantly decreased CD26+ cell numbers and attenuated the plasma CD26/DPP IV activity ( P < 0.001). Furthermore, short-term CsA treatment significantly improved the perfusion of ischemic limbs and decreased the spontaneous digital amputation rate. In summary, CsA manipulates the mobilization of EPCs into the circulation via the CD26/DPP IV system. Short-term CsA treatment has beneficial effects on angiogenesis of ischemic tissues.

Download Full-text

The effect of short-term, low-dose tricyclic and tetracyclic antidepressant treatment on satiation, postnutrient load gastrointestinal symptoms and gastric emptying: a double-blind, randomized, placebo-controlled trial

Neurogastroenterology & Motility ◽

10.1111/j.1365-2982.2007.01029.x ◽

2008 ◽

Vol 20 (3) ◽

pp. 220-227 ◽

Cited By ~ 36

Author(s):

r. s. choung ◽

f. cremonini ◽

p. thapa ◽

a. r. zinsmeister ◽

n. j. talley

Keyword(s):

Gastric Emptying ◽

Low Dose ◽

Antidepressant Treatment ◽

Controlled Trial ◽

Gastrointestinal Symptoms ◽

Short Term ◽

Double Blind ◽

Tetracyclic Antidepressant

Download Full-text

Quality of life, diagnosis, and treatment of patients with major depression: a prospective cohort study in primary care

Brazilian Journal of Psychiatry ◽

10.1590/s1516-44462011000300007 ◽

2011 ◽

Vol 33 (3) ◽

pp. 245-251 ◽

Cited By ~ 7

Author(s):

Ana Flávia Barros da Silva Lima ◽

Marcelo Pio de Almeida Fleck

Keyword(s):

Quality Of Life ◽

Primary Care ◽

Cohort Study ◽

Major Depression ◽

Antidepressant Treatment ◽

Epidemiologic Studies ◽

World Health ◽

World Health Organization Quality

OBJECTIVE: To describe the demographic and clinical characteristics, adequacy of antidepressant treatment, and changes in quality of life of patients with major depression receiving follow-up care from primary care centers. METHOD: A cohort study was performed in which major depression patients were followed-up over a nine-month period. Several evaluation instruments were used, including the World Health Organization Quality of Life and the Quality of Life-Depression, Centers for Epidemiologic Studies-Depression questionnaires. RESULTS: The sample comprised 179 individuals, mostly female (73%), with a mean age of 38 years and mean education of 9 years. At the end of the follow-up period, 42% of the individuals still presented with major depression, 25% had complete symptom remission, and only 9% were properly treated with antidepressants. In relation to quality of life, there were significant differences especially between baseline and after nine months in almost all measures. CONCLUSION: This study demonstrated that depressive symptoms are poorly recognized and that treatment is often inadequate for patients followed-up in primary care units in the south of Brazil. Most of the patients continued to have symptoms of depression over the nine-month period which were associated with impaired quality of life.

Download Full-text

Assessment of mature serum brain-derived neurotrophic factor (BDNF) is not superior to total serum BDNF in prediction of antidepressant treatment outcome

European Psychiatry ◽

10.1016/j.eurpsy.2016.01.1480 ◽

2016 ◽

Vol 33 (S1) ◽

pp. S410-S410 ◽

Cited By ~ 1

Author(s):

A. Eckert ◽

T. Mikoteit ◽

J. Beck ◽

U.M. Hemmeter ◽

S. Brand ◽

...

Keyword(s):

Treatment Outcome ◽

Treatment Response ◽

Rating Scale ◽

Antidepressant Treatment ◽

Serum Levels ◽

Total Serum ◽

Enzyme Linked Immunosorbent Assay ◽

Functional Link ◽

Neurotrophic Activity ◽

Serum Bdnf

BackgroundSerum BDNF levels are decreased in major depressive disorder (MDD) and tend to normalize under antidepressant treatment, serving as a treatment outcome predictor. BDNF is initially synthetized as precursor protein proBDNF and is cleaved to mature BDNF (mBDNF) while only the latter exerts neurotrophic activity.AimThe aim was to explore if a specific enzyme-linked immunosorbent assay (ELISA) kit for mBDNF in serum would be superior to the unspecific assessment of total serum BDNF in predicting treatment response in MDD.MethodsTwenty-five patients with MDD underwent standardized treatment with duloxetine. Severity of depression was measured by Hamilton Depression Rating Scale (HDRS) at baseline (BL), after one (W1), two (W2) and six weeks (W6) of treatment. Treatment response was defined as a HDRS ≥ 50% reduction of BL score at W6. mBDNF and total BDNF serum levels were determined at BL, W1 and W2.ResultsA high and stable correlation was found between mBDNF and total BDNF serum levels over all measurements. The predictive value of mBDNF BL levels and mBDNFΔW1 to response was similar to that of total BDNF BL and total BDNFΔW1. The assessment of serum mBDNF was not superior to total BDNF in prediction of treatment outcome.ConclusionsNot only baseline total BDNF but also mBDNF is predictive to treatment outcome. The later might represent the main player in this respect, which supports the idea of a functional link between neuroplasticity and MDD.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Download Full-text

Tolerability of mirtazapine vs SSRIs in short term treatment of major depression

European Neuropsychopharmacology ◽

10.1016/s0924-977x(99)80171-0 ◽

1999 ◽

Vol 9 ◽

pp. 229 ◽

Cited By ~ 1

Author(s):

C.M.E. Kremer ◽

J.T.H. Helsdingen ◽

J.A. Schutte ◽

E. Vester

Keyword(s):

Major Depression ◽

Term Treatment ◽

Short Term ◽

Short Term Treatment

Download Full-text

Comparative Efficacy and Safety of Sertraline Versus Nortriptyline in Major Depression in Patients 70 and Older

International Psychogeriatrics ◽

10.1017/s104161029900561x ◽

1999 ◽

Vol 11 (1) ◽

pp. 85-99 ◽

Cited By ~ 41

Author(s):

Sanford I. Finkel ◽

Ellen M. Richter ◽

Cathryn M. Clary

Keyword(s):

Major Depression ◽

Rating Scale ◽

Antidepressant Treatment ◽

Change Score ◽

Attrition Rate ◽

Double Blind ◽

Almost All ◽

Positive Effect ◽

Population Segment

Background. Few randomized, double-blind studies that examine antidepressant treatment in patients 70 years and older are available. To provide additional data on the safety and efficacy of antidepressants in this rapidly growing population segment, a subgroup analysis of a larger sertraline vs. nortriptyline elderly depression treatment study was performed. Methods. Outpatients (N = 76) who met DSM-III-R criteria for major depression with a minimum Hamilton Depression Rating Scale (HAM-D) severity score of 18 were randomized to 12 weeks of flexible dose treatment with sertraline (50–150 mg) or nortriptyline (25–100 mg). Results. Both treatments significantly improved depression as measured by the HAM-D and Clinical Global Impression scales. At Weeks 10, 12, and endpoint, sertraline demonstrated a significantly greater reduction in depression severity compared to nortriptyline as measured by improvement on the 24-item HAM-D (mean adjusted change score of 14.8 vs. 7.6, respectively, at Week 12; p = .001). Sixty-five percent of sertraline-treated patients were responders by Week 12 (50% or greater reduction from baseline in 24-item HAM-D score) compared to 26% of nortriptyline-treated patients (p < .05). Sertraline treatment had a significantly more positive effect, when compared to nortriptyline, across almost all associated measures of cognitive function, energy, anxiety, and quality of life and was better tolerated than nortriptyline, with a lower attrition rate/side effect burden. Conclusion. The efficacy advantage of sertraline appeared to be even greater in this subgroup of older patients drawn from a larger treatment study of depression that included elderly individuals over the age of 60.

Download Full-text